Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7387613 | 0.94 | MEN1 (0.42) | MAP4K4MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL2890076 | 0.89 | PKM (0.47) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL6232755 | 0.89 | MEN1 (0.49) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL10305747 | 0.87 | MAP4K4 (0.46) | MAP4K4HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL24915019 | 0.87 | KDM4E (0.50) | MAP4K4MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL25923116 | 0.83 | TPMT (0.48) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL2178704 | 0.83 | CA12 (0.46) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL1025862 | 0.82 | MEN1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL4726163 | 0.82 | EPHX2 (0.42) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL9396335 | 0.82 | KDM4E (0.55) | MEN1KMT2AMAPTPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-12-15 | — | — | US | disclosed |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-21 | — | — | US | disclosed |
| EP-3335734-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | Industrial Technology Research Institute (TW) | 2018-06-20 | — | — | EP | disclosed |
| WO-2008119772-A1 | AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES | MEDIVIR AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119773-A1 | AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES | MEDIVIR AB (SE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | ADCY7, ADCY1, ADCY9 | MAP4K4 4112/4885MEN1 2210/4885KMT2A 1373/4885 |
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | ADCY7, ADCY1, ADCY9 | MAP4K4 4112/4885MEN1 2210/4885KMT2A 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.